

Cameron D. Thomas, Pharm.D., Ph.D.

R.C. Wilson Pharmacy Building
250 W. Green Street
Athens, GA 30602
Phone: (706) 542-5317
Email: CDThomas@uga.edu

EDUCATION

Doctor of Philosophy – Clinical Pharmaceutical Sciences University of Florida College of Pharmacy	2020 – 2025
Graduate Certificate – Precision Medicine University of Florida Pharmacogenomics & Precision Medicine	2020 – 2021
Doctor of Pharmacy University of Florida College of Pharmacy	2012 – 2016
Associate of Arts Florida Gateway College Pre-Pharmacy Curriculum	2011 – 2012

PROFESSIONAL WORK EXPERIENCE

Assistant Professor University of Georgia – College of Pharmacy Department of Clinical and Administrative Pharmacy Athens, GA	2025 – Present
Clinical Staff Pharmacist – PRN UF Health Shands Hospital Gainesville, FL	2022 – 2025
T32 PARADIGM Fellow in Genomic Medicine University of Florida – College of Pharmacy Gainesville, FL	2018 – 2021
PGY-2 Clinical Pharmacogenetics Resident St. Jude Children’s Research Hospital Memphis, TN	2017 – 2018
PGY-1 Pharmacy Resident UF Health Jacksonville Jacksonville, FL	2016 – 2017

Biomedical Research Intern

2014 – 2016

Nemours Children's Specialty Care
Jacksonville, FL

Pharmacy Intern

2012 – 2016

CVS/Pharmacy
Macclenny, FL

Research Intern

University of Florida – College of Pharmacy
Gainesville, FL

2014

PUBLICATIONS

Ortega-Paz L*, **Thomas CD***, Laudani C, Giordano S, Franchi F, Tunehag KR, Rollini F, Durukan S, Rossi JS, Farahmandsadr M, Stouffer GA, Been L, Keeley EC, Duarte JD, Beitelshes AL, Lee CR, Cavallari LH, Angiolillo DJ. Impact of Race on Profiles of Platelet Reactivity and Clinical Outcomes in Clopidogrel-Treated Participants. *Clin Pharmacol Ther.* 2025 Aug 28. doi: 10.1002/cpt.70045. Epub ahead of print. *Contributed equally.

Patel RC*, **Thomas CD***, Rossi JS, Franchi F, Keeley EC, Beitelshes AL, Duarte JD, Ortega-Paz L, Kulick N, Winget M, Nguyen AB, Yang WE, Venkatesh S, Angiolillo DJ, Cavallari LH, Lee CR, Stouffer GA. CYP2C19 Phenotype, P2Y₁₂ Inhibitor Selection, and Clinical Outcomes in Patients on Maintenance Clopidogrel Therapy. *J Am Heart Assoc.* 2025;14:e041634. doi: 10.1161/JAHA.125.041634. *Contributed equally.

Cavallari LH,* Lee CR,* Franchi F, Keeley EC, Rossi JS, **Thomas CD**, Gong Y, McDonough CW, Starostik P, Al Saeed MJ, Been L, Kulick N, Malave J, Mulrenin IR, Nguyen AB, Terrell JN, Tillotson G, Beitelshes AL, Winterstein AG, Stouffer GA, Angiolillo DJ. Precision Antiplatelet Therapy after Percutaneous Coronary Intervention (Precision PCI) Registry - Informing optimal antiplatelet strategies. *Clin Transl Sci.* 2024;17(8):e70004. doi: 10.1111/cts.70004. *Contributed equally.

AlSaeed MJ, **Thomas CD**, Franchi F, Keeley EC, Duarte JD, Gong Y, Rossi JS, Beitelshes AL, Stouffer GA, Lee CR, Angiolillo DJ, Cavallari LH. Evaluating the Effect of Estimating Renal Function With the CKD-EPI 2021 Equation on the ABCD-GENE Score for Clopidogrel Response Prediction. *Clin Pharmacol Ther.* 2024;116(5):1227-1230. doi: 10.1002/cpt.3385.

Duarte JD, **Thomas CD**, Lee CR, Huddart R, Agundez JAG, Baye JF, Gaedigk A, Klein TE, Lanfear DE, Monte AA, Nagy M, Schwab M, Stein CM, Uppugunduri CRS, van Schaik RHN, Donnelly RS, Caudle KE, Luzum JA. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy. *Clin Pharmacol Ther.* 2024 Jul 1. doi: 10.1002/cpt.3351.

Thomas CD, Franchi F, Rossi JS, Keeley EC, Anderson RD, Beitelshes AL, Duarte JD, Ortega-Paz L, Gong Y, Kerensky RA, Kulick N, McDonough CW, Nguyen AB, Wang Y, Winget M, Yang WE, Johnson JA, Winterstein AG, Stouffer GA, Angiolillo DJ, Lee CR,* Cavallari LH.* Effectiveness of Clopidogrel vs Alternative P2Y₁₂ Inhibitors Based on the ABCD-GENE Score. *J Am Coll Cardiol.* 2024 Apr 16;83(15):1370-1381. doi: 10.1016/j.jacc.2024.02.015. *Contributed equally.

Tunehag KR, **Thomas CD**, Franchi F, Rossi JS, Keeley EC, Anderson RD, Beitelshes AL, Duarte JD, Gong Y, Kerensky RA, McDonough CW, Nguyen AB, Ortega-Paz L, Venkatesh S, Wang Y, Johnson JA, Winterstein AG, Stouffer GA, Angiolillo DJ, Cavallari LH, Lee CR. *CYP2C19* Genotype Is Associated With Adverse Cardiovascular Outcomes in Black Patients Treated With Clopidogrel Undergoing Percutaneous Coronary Intervention. *J Am Heart Assoc*. 2024 Jun 18;13(12):e033791. doi: 10.1161/JAHA.123.033791.

Cicali EJ, **Thomas CD**, Elchynski A, Alam B, Dalton R, Davis R, Eken E, Estores D, Nguyen K, Cavallari LH, Wiisanen K. Implementation of *CYP2C19* genotyping to guide proton pump inhibitor use at an academic health center. *Am J Health Syst Pharm*. 2023:zxad099. DOI: 10.1093/ajhp/zxad099. Epub ahead of print.

Thomas CD, Williams AK, Lee CR, Cavallari LH. Pharmacogenetics of P2Y₁₂ Receptor Inhibitors. *Pharmacotherapy*. 2023;43(2):158-175. DOI: 10.1002/phar.2758.

Wang Y, Cavallari LH, Brown JD, **Thomas CD**, Winterstein AG. Assessing the Clinical Treatment Dynamics of Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention in the US. *JAMA Netw Open*. 2023;6(4):e238585. DOI: 10.1001/jamanetworkopen.2023.8585.

Cavallari LH, Limdi NA, Beitelshes AL, Lee JC, Duarte JD, Franchi F, Tuteja S, Giri J, Empey PE, Kreutz RP, Skaar TC, Allen JM, Coons JC, Gong Y, McDonough CW, Stevenson JM, **Thomas CD**, Johnson JA, Stouffer GA, Angiolillo DJ, Lee CR. Evaluation of Potential Racial Disparities in *CYP2C19*-Guided P2Y₁₂ Inhibitor Prescribing after Percutaneous Coronary Intervention. *Clin Pharmacol Ther*. 2023;113(3):615-623. DOI: 10.1002/cpt.2776.

Thomas CD, Franchi F, Keeley EC, Rossi JS, Winget M, Anderson RD, Dempsey AL, Gong Y, Gower MN, Kerensky RA, Kulick N, Malave JG, McDonough CW, Mulrenin IR, Starostik P, Beitelshes AL, Johnson JA, Stouffer GA, Winterstein AG, Angiolillo DJ, Lee CR, Cavallari LH. Impact of the ABCD-GENE Score on Clopidogrel Clinical Effectiveness after PCI: A Multi-site, Real-world Investigation. *Clin Pharmacol Ther*. 2022;112(1):146-155. DOI: 10.1002/cpt.2612.

Cavallari LH, Cicali E, Wiisanen K, Fillingim RB, Chakraborty H, Myers RA, Blake KV, Asiyanbola B, Baye JF, Bronson WH, Cook KJ, Elwood EN, Gray CF, Gong Y, Hines L, Kannry J, Kucher N, Lynch S, Nguyen KA, Obeng AO, Pratt VM, Prieto HA, Ramos M, Sadeghpour A, Singh R, Rosenman M, Starostik P, **Thomas CD**, Tillman E, Dexter PR, Horowitz CR, Orlando LA, Peterson JF, Skaar TC, Van Driest SL, Volpi S, Voora D, Parvataneni HK, Johnson JA; IGNITE Pragmatic Trials Network. Implementing a Pragmatic Clinical Trial to Tailor Opioids for Acute Pain on behalf of the IGNITE ADOPT PGx Investigators. *Clin Transl Sci*. 2022;15(10):2479-2492. DOI: 10.1111/cts.13376.

Beitelshes AL, **Thomas CD**, Empey PE, Stouffer GA, Angiolillo DJ, Franchi F, Tuteja S, Limdi NA, Lee JC, Duarte JD, Kreutz RP, Skaar TC, Coons JC, Giri J, McDonough CW, Rowland R, Stevenson JM, Thai T, Vesely MR, Wellen JT, Johnson JA, Winterstein AG, Cavallari LH, Lee CR on behalf of the IGNITE Network Pharmacogenetics Working Group. *CYP2C19* Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention

in Diverse Clinical Settings. *J Am Heart Assoc.* 2022;11(4):e024159. DOI: 10.1161/JAHA.121.024159.

Cicali EJ, Elchynski AL, Cook KJ, Houder JT, **Thomas CD**, Smith DM, Elsey AR, Johnson JA, Cavallari LH, Wiisanen K. How to Integrate CYP2D6 Phenoconversion into Clinical Pharmacogenetics: A Tutorial. *Clin Pharmacol Ther.* 2021;110(3):677-687. DOI: 10.1002/cpt.2354.

Thomas CD, Parvataneni HK, Gray CF, Deen JT, Prieto HA, Pulido LF, Elsey AR, Elwood EN, Starostik P, Gong Y, Fillingim RB, Johnson JA, Cavallari LH. A Hybrid Implementation-Effectiveness Randomized Trial of *CYP2D6*-guided Postoperative Pain Management. *Genet Med.* 2021;23(4):621-8. DOI: 10.1038/s41436-020-01050-4.

Lee CR, **Thomas CD**, Beitelshes AL, Tuteja S, Empey PE, Lee JC, Limdi NA, Duarte JD, Skaar TC, Chen Y, Cook K, Dillon C, Franchi F, Gong Y, Kreutz RP, McDonough CW, Weck KE, Angiolillo DJ, Johnson JA, Stouffer GA, Cavallari LH on behalf of the IGNITE Network Pharmacogenetics Working Group. Impact of the *CYP2C19*17* Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. *Clin Pharmacol Ther.* 2021;109(3):705-15. DOI: 10.1002/cpt.2039.

Thomas CD, Mosley SA, Kim S, Lingineni K, El Rouby N, Langaee T, Gong Y, Wang D, Schmidt S, Binkley P, Estores DS, Feng K, Kim H, Kinjo M, Li Z, Fang L, Chapman A, Cooper-DeHoff RM, Gums J, Hamadeh IS, Zhao L, Schmidt S, Frye RF, Johnson JA, Cavallari LH. Examination of Metoprolol Pharmacokinetics and Pharmacodynamics across *CYP2D6* Genotype-Derived Activity Scores. *CPT Pharmacometrics Syst Pharmacol.* 2020;9(12):678-85. DOI: 10.1002/psp4.12563.

Thomas CD, Johnson JA. Pharmacogenetic Factors Affecting β -blocker Metabolism and Response. *Expert Opin Drug Metab Toxicol.* 2020;16(10):953-64. DOI: 10.1080/17425255.2020.1803279.

Lima JJ, **Thomas CD**, Barbarino J, Desta Z, Van Driest SL, El Rouby N, Johnson JA, Cavallari LH, Shakhnovich V, Thacker DL, Scott SA, Schwab M, Uppugunduri CRS, Formea CM, Franciosi JP, Sangkuhl K, Gaedigk A, Klein TE, Gammal RS, Furuta T. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for *CYP2C19* and Proton Pump Inhibitor Dosing. *Clin Pharmacol Ther.* 2020. DOI: 10.1002/cpt.2015.

Thomas CD, Dupree LH, DeLosSantos M, Ferreira JA. Evaluation of the Protective Effects of β -blockers in the Management of Acute Exacerbations of Chronic Obstructive Pulmonary Disease. *J Clin Pharm Ther.* 2019;44(1):109-114. DOI: 10.1111/jcpt.12767.

Franciosi J, Mougey E, Williams A, Gomez-Suarez R, **Thomas CD**, Creech C, George K, Corao D, Lima J. Association between CYP2C19 Extensive Metabolizer Phenotype and Childhood Anti-reflux Surgery Following Failed Proton Pump Inhibitor Medication Treatment. *Eur J Pediatr* 2018;177(1):69-77. DOI: 10.1007/s00431-017-3051-4.

Franciosi J, Mougey E, Williams A, Gomez-Suarez R, **Thomas CD**, Creech C, George K, Corao D, Lima J. Association between *CYP2C19*17* Alleles and pH Probe Testing Outcomes in Children with Symptomatic Gastroesophageal Reflux. *J Clin Pharmacol* 2018;58(1):89-96. DOI:10.1002/jcph.977.

Motycka C, Egelund E, **Thomas CD**. The Impact of Medical Marijuana on Pharmacy Practice. *Advances in Pharmacology and Pharmacy* 2018;6(1):12-17. DOI: 10.13189/app.2018.060102.

MacFadyen K, Loveless R, DeLucca B, Wardley K, Deogan S, **Thomas CD**, Peris J. Peripheral Oxytocin Administration Reduces Ethanol Consumption in Rats. *Pharmacol Biochem Behav* 2016;140:27-32. DOI: 10.1016/j.pbb.2015.10.014.

PUBLISHED ABSTRACTS

Thomas CD, Rossi JS, Franchi F, Keeley EC, Paz LO, Beitelshes AL, Duarte JD, Johnson JA, Stouffer GA, Angiolillo DJ, Lee CR, Cavallari LH. Evaluation of clinical outcomes among black versus non-black patients after PCI and CYP2C19 genotyping: A multi-site, real-world investigation. *J Am Coll Cardiol*. 2024;83(13, Supplement):850.

AlSaeed MJA, **Thomas CD**, Franchi F, Keeley E, Rossi J, Beitelshes A, Duarte J, Angiolillo DJ, Stouffer GA, Lee CR, Cavallari L. Evaluating the impact of estimating renal function with the ckd-epicr 2021 equation on the abcd-gene score among black and non-black patients who underwent pci. *J Am Coll Cardiol*. 2024;83(13):1257.

Paz LO, Giordano S, Franchi F, Rollini F, Been L, Al Saleh T, Uzunoglu EC, Maldonado AMP, Suryadevara S, Soffer D, Zenni MM, Mahowald M, **Thomas CD**, Cavallari L, Angiolillo DJ. Impact of race on platelet reactivity profiles in patients on clopidogrel treatment. *J Am Coll Cardiol*. 2024;83(13):849.

Thomas CD, Franchi F, Keeley EC, Rossi JS, Anderson RD, Gong Y, Kerensky RA, McDonough CW, Nguyen AB, Winget M, Duarte JD, Beitelshes AL, Johnson JA, Stouffer GA, Winterstein AG, Angiolillo DJ, Lee CR, Cavallari LH. Impact of the ABCD-GENE Score on P2Y₁₂ Inhibitor Clinical Effectiveness after PCI: A Multi-site, Real-world Investigation. *J Am Coll Cardiol*. 2023 Mar, 81 (8_Supplement) 786. [https://doi.org/10.1016/S0735-1097\(23\)01230-5](https://doi.org/10.1016/S0735-1097(23)01230-5).

Wang Y, Cavallari LH, Brown J, **Thomas CD**, Winterstein AG. Association Between Bleeding Risk and Initial P2Y₁₂ Inhibitor Selection and De-escalation Among Patients with Acute Coronary Syndrome and Percutaneous Coronary Intervention. *Clin Pharmacol Ther*. 2023;113(S1):S6.

Thomas CD, Franchi F, Rossi JS, Beitelshes AL, Keeley EC, Gong Y, Johnson JA, Winget M, Anderson RD, Kerensky RA, McDonough CW, Stouffer GA, Angiolillo DJ, Lee CR, Cavallari LH. Impact of *CYP2C19* genotype on prediction of cardiovascular events with the ABCD-GENE score among patients receiving *CYP2C19*-guided antiplatelet therapy after PCI. *Clin Pharmacol Ther*. 2022;111(S1):S68.

Winget M, Mulrenin IR, Gower MN, Kulick N, **Thomas CD**, Cavallari LH, Weck KE, Rossi JS, Stouffer GA, Lee CR. Evaluating the impact of the ABCD-GENE score on antiplatelet therapy outcomes following percutaneous coronary intervention in a real-world clinical setting. *Clin Pharmacol Ther.* 2022;111(S1):S75.

Thomas CD, Yang G, Elbalkiny S, Huang Y, Nahid N, Nguyen N, Mehanna M, Boerwinkle E, Chapman AB, Gums JG, Gong Y, Johnson JA, Cooper-DeHoff RM, McDonough CW. Genetic association of uric acid change after thiazide/thiazide-like diuretic treatment – analysis of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) studies. *Clin Pharmacol Ther.* 2022;111(S1):S52.

Thomas CD, Beitelshes AL, Franchi F, Shahin MH, Kovar L, Gong Y, McDonough CW, Johnson JA, Angiolillo DJ, Cavallari LH. Impact of the ABCD-GENE Score on Cardiovascular Outcomes with *CYP2C19*-Guided Antiplatelet Therapy After PCI: A Multi-site, Real-world Investigation. *Clin Pharmacol Ther.* 2021;109(S1):S5-S88.

Thomas CD, Empey PE, Beitelshes AL, Tuteja S, Angiolillo DJ, Limdi NA, Lee JC, Duarte JD, Skaar TC, Chen Y, Coons JC, Dillon C, Franchi F, Gong Y, Kreutz RP, McDonough CW, Stouffer GA, Johnson JA, Lee CR, Cavallari LH. Cardiovascular outcomes according to clinical presentation with *CYP2C19*-genotype guided antiplatelet therapy in patients undergoing PCI: a multi-site investigation in real-world settings. *JACCP.* 2020;3(12):1629-30.

Thomas CD, Elsey AR, Starostik P, Gong Y, Deen JT, Pulido LF, Prieto HA, Fillingim RB, Gray CF, Parvataneni HK, Johnson JA, Cavallari LH. Precise Pain Control: Feasibility and Efficacy of a Preemptive *CYP2D6*-Genotype Guided Postoperative Pain Management Paradigm. *Clin Pharmacol Ther.* 2020;107(S1):S5-S121.

Cicali EJ, Cook KJ, Arwood M, Staley B, **Thomas CD**, Dalton R, Elsey AR, Cavallari LH, Johnson JA, Cooper-DeHoff RM, Wiisanen K. Development of Standardized Clinical Resources to Support Implementation of a Preemptive Pharmacogenomic Testing Panel. *Clin Pharmacol Ther.* 2020;107(S1):S5-S121.

POSTER PRESENTATIONS (presenting author)

Kapalczynski MA, **Thomas CD**, McDonough CW, Keeley EC, Gong Y, Cavallari LH, Rouhizadeh M. *Developing a Bleeding Outcomes Documentation Lexicon for Unstructured Clinical Notes*. Florida Society of Health-System Pharmacists; 2025 Annual Meeting. Orlando, FL. August 2025.

Thomas CD, Rossi JS, Franchi F, Keeley EC, Paz LO, Beitelshes AL, Duarte JD, Johnson JA, Stouffer GA, Angiolillo DJ, Lee CR, Cavallari LH. *Evaluation of Clinical Outcomes Among Black versus Non-Black Patients after PCI and CYP2C19 Genotyping: A Multi-Site, Real-World Investigation*. American College of Cardiology; 2024 Annual Meeting. Atlanta, Ga. April 2024.

Thomas CD, Franchi F, Keeley EC, Rossi JS, Anderson RD, Gong Y, Kerensky RA, McDonough CW, Nguyen AB, Winget M, Duarte JD, Beitelshes AL, Johnson JA, Stouffer GA, Winterstein AG, Angiolillo DJ, Lee CR, Cavallari LH. *Impact of the ABCD-GENE Score on P2Y₁₂ Inhibitor Clinical Effectiveness after PCI: A Multi-site, Real-world Investigation*. American College of Cardiology & World Congress of Cardiology; 2023 Annual Meeting. New Orleans, LA. March 2023.

Thomas CD, Franchi F, Rossi JS, Beitelshes AL, Keeley EC, Gong Y, Johnson JA, Winget M, Anderson RD, Kerensky RA, McDonough CW, Stouffer GA, Angiolillo DJ, Lee CR, Cavallari LH. *Impact of CYP2C19 genotype on prediction of cardiovascular events with the ABCD-GENE score among patients receiving CYP2C19-guided antiplatelet therapy after PCI*. ASCPT; 2022 Annual Meeting. January and March 2022.

Thomas CD, Yang G, Elbalkiny S, Huang Y, Nahid NA, Nguyen N, Mehanna M, Boerwinkle E, Chapman AB, Gums JG, Gong Y, Johnson JA, Cooper-DeHoff RM, McDonough CW. *Genetic Association of Uric Acid Change After Thiazide/Thiazide-like Diuretic Treatment – Analysis of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Studies*. ASCPT; 2022 Annual Meeting. March 2022.

Winget M, Mulrenin IR, Gower MN, Kulick N, **Thomas CD**, Cavallari LH, Weck KE, Rossi JS, Stouffer GA, Lee CR. *Evaluating the impact of the ABCD-GENE score on antiplatelet therapy outcomes following percutaneous coronary intervention in a real-world clinical setting*. ASCPT; 2022 Annual Meeting. March 2022.

Thomas CD, Franchi F, Rossi JS, Beitelshes AL, Keeley EC, Gong Y, Johnson JA, Anderson RD, Kerensky RA, McDonough CW, Stouffer GA, Angiolillo DJ, Lee CR, Cavallari LH. *Examining cardiovascular outcomes with the ABCD-GENE score among patients receiving CYP2C19-guided antiplatelet therapy after PCI*. PGRN-ASHG; 2021 Symposium & Posters. October 2021.

Thomas CD, Beitelshes AL, Franchi F, Shahin MH, Kovar L, Gong Y, McDonough CW, Johnson JA, Angiolillo DJ, Cavallari LH. *Impact of the ABCD-GENE Score on Cardiovascular Outcomes with CYP2C19-Guided Antiplatelet Therapy After PCI: A Multi-site, Real-world Investigation*. ASCPT; 2021 Annual Meeting. March 2021.

Thomas CD, Empey PE, Beitelshes AL, Tuteja S, Angiolillo DJ, Limdi NA, Lee JC, Duarte JD, Skaar TC, Chen Y, Coons JC, Dillon C, Franchi F, Gong Y, Kreutz RP, McDonough CW, Stouffer GA, Johnson JA, Lee CR, Cavallari LH. *Cardiovascular outcomes according to clinical presentation with CYP2C19-genotype guided antiplatelet therapy in patients undergoing PCI: a multi-site investigation in real-world settings*. ACCP; 2020 Annual Meeting. October 2020.

Thomas CD, Elsey AR, Starostik P, Gong Y, Deen JT, Pulido LF, Prieto HA, Fillingim R, Gray CF, Parvataneni HK, Johnson JA, Cavallari LH. *Precise Pain Control: Feasibility and Efficacy of a Preemptive CYP2D6-genotype Guided Post-operative Pain Management Paradigm*. ASCPT; 2021 Annual Meeting. March 2021.

Cicali EJ, Cook KJ, Arwood M, Staley B, **Thomas CD**, Dalton R, Elsey AR, Cavallari LH, Johnson JA, Cooper-DeHoff RM, Wiisanen K. *Development of Standardized Clinical Resources to Support Implementation of a Preemptive Pharmacogenomic Testing Panel*. ASCPT; 2020 Annual Meeting. Houston, TX. Tentative March 2020.

Thomas CD, Lee CR, Angiolillo DJ, Duarte JD, Chen Y, Franchi F, Gong Y, McDonough CW, Stouffer GA, Johnson JA, Cavallari LH. *ACS vs. Non-ACS and MACE: Evaluating Outcomes Following CYP2C19-genotype Guided Antiplatelet Therapy*. UF Precision Medicine Conference; 2020 Annual Meeting. Orlando, FL. 21 February 2020.

Thomas CD, Lee CR, Angiolillo DJ, Duarte JD, Chen Y, Franchi F, Gong Y, McDonough CW, Stouffer GA, Johnson JA, Cavallari LH. *ACS and MACE: Outcomes following CYP2C19-genotype guided antiplatelet therapy*. University of Florida; College of Pharmacy – 33rd Annual Research Showcase. Gainesville, FL. 10 February 2020.

Thomas CD, Elsey AR, Starostik P, Gong Y, Deen JT, Pulido LF, Prieto HA, Fillingim R, Gray CF, Parvataneni HK, Johnson JA, Cavallari LH. *A Pilot Clinical Trial of a CYP2D6 Genotype-Guided Pain Management Strategy in Patients Undergoing Total Joint Arthroplasty*. ASHG; 2019 PGRN Poster Session. Houston, TX. 17 October 2019.

Thomas CD, Gray CF, Gong Y, Elsey AR, Starostik P, Fillingim R, Parvataneni HK, Johnson JA, Cavallari LH. *Implementing Genomics in Practice (IGNITE): Feasibility of a CYP2D6 Genotype-Guided Pain Management Strategy in Patients Undergoing Arthroplasty Surgery*. NHGRI; 2019 NHGRI Research Training & Career Development Annual Meeting. St. Louis, MO. 8 April 2019.

Thomas CD, Mosley SA, El Rouby N, Kim S, Lingineni K, Langae T, Gong Y, Johnson JA, Schmidt SO, Schmidt S, Frye RF, Cavallari LH. *Determination of CYP2D6 Phenotyping for Metoprolol using the CYP2D6 Genotype-derived Activity Score: Results from a Prospective, Clinical Trial*. ASCPT; 2019 Annual Meeting. Washington, D.C. 13 March 2019.

Thomas CD, Mosley SA, El Rouby N, Kim S, Lingineni K, Langae T, Gong Y, Johnson JA, Schmidt SO, Schmidt S, Frye RF, Cavallari LH. *Determination of CYP2D6 Phenotyping for Metoprolol using the CYP2D6 Genotype-derived Activity Score: Results from a Prospective, Clinical Trial*. University of Florida; College of Pharmacy – 32nd Annual Research Showcase. Gainesville, FL. 11 February 2019.

Hoshitsuki K, Haidar CE, Crews KR, **Thomas CD**, Smith C, Yang W, Broeckel U, Hankins JS, Relling MV. *Clinical Implementation of Preemptive G6PD Genotyping through PG4KDS*. PGRN; 2018 PGRN-ASHG Symposium. San Diego, CA. 15 October 2018.

Thomas CD, Crews KR, Haidar CE, Evans WE, Pui CH, Relling MV, Inaba H, Yang JJ. *Development of a Precision Medicine Approach to Guide 6-Mercaptopurine Dosing in a Frontline Clinical Trial for Childhood Acute Lymphoblastic Leukemia and Lymphoma*. HOPA; 2018 Annual Conference. Denver, CO. 22 March 2018.

Thomas CD, Haidar CE, Crews KR, Hoffman JM, Relling MV. *Implementing Preemptive Clinical Pharmacogenetics with PG4KDS: Reporting on Six Years of Experience*. ASHP; 2017 Midyear Clinical Meeting. Orlando, FL. 6 December 2017.

Thomas CD, Deogan S, Delucca B, MacFadyen K, Loveless R, Peris J, Martynyuk A. *Comparison of the Effects of Maternal Separation versus Neonatal Sevoflurane Exposure on Ethanol Intake in Adult Rats*. University of Florida; College of Pharmacy – 28th Annual Research Showcase. Gainesville, FL. 19 February 2015.

Loveless R, MacFadyen K, Delucca B, **Thomas CD**, Deogan S, Peris J. *Effects of Peripheral Oxytocin injections on Alcohol Consumption in Rats*. University of Florida; College of Pharmacy – 28th Annual Research Showcase. Gainesville, FL. 19 February 2015.

Thomas CD, Pearce J, Abu-Sawwa R, Van Putten, Gorospe M. *Optimization of the Automated Dispensing Cabinet*. UF Health Jacksonville: Clinical Research Presentations. Jacksonville, FL. 2 December 2013.

INVITED PRESENTATIONS

Impact of the ABCD-GENE Score on P2Y ₁₂ Inhibitor Clinical Effectiveness after PCI: A Multi-site, Real-world Investigation. Pharmacotherapy Grand Rounds. Gainesville, FL.	March 2023
Graduate Program in Precision Medicine: A Former Student's Perspective. UF Pharmacogenomics & Precision Medicine Program. Webinar.	March 2022
Impact of <i>CYP2C19</i> genotype on cardiovascular events with the ABCD-GENE score. UF College of Pharmacy Annual Research Showcase Oral Competition. Gainesville, FL.	February 2022
Genetic and Clinical Predictors of Clopidogrel Response – Optimization of P2Y ₁₂ Inhibitor Prescribing. Pharmacotherapy Grand Rounds. Gainesville, FL.	January 2022
PARADIGM: A Model Training Program. T32 Program for Applied Research and Development in Genomic Medicine Annual Retreat. Gainesville, FL.	June 2021
A real-world investigation of the ABCD-GENE score on cardiovascular outcomes. UF College of Pharmacy Annual Research Showcase Oral Competition. Gainesville, FL.	April 2021
Feasibility and Efficacy of <i>CYP2D6</i> Genotyping in Patients Undergoing Total Joint Arthroplasty. Pharmacotherapy Grand Rounds. Gainesville, FL.	January 2021
Cardiovascular outcomes according to clinical presentation with <i>CYP2C19</i> -guided antiplatelet therapy in patients undergoing PCI: a multi-site investigation in real-world settings. 2020 ACCP Annual Meeting.	October 2020

Pharmacogenetics of β -blockers: CPIC Proposal for ADRB1, GRK5 and CYP2D6. Clinical Pharmacogenetics Implementation Consortium Monthly Business Meeting. Webinar.	September 2020
Evidence-Based Pharmacogenomics: A Crucial Piece of the Implementation Puzzle. 2020 University of Florida Precision Medicine Conference. Orlando, FL.	February 2020
A Pilot Clinical Trial of a CYP2D6 Genotype-Guided Pain Management Strategy in Patients Undergoing Total Joint Arthroplasty. NHGRI Genomic Medicine T32 Session. ASHG 2019 Annual Meeting. Houston, TX.	October 2019
Implementing Genomics in Practice (IGNITE): Feasibility of a CYP2D6 Genotype-Guided Pain Management Strategy in Patients Undergoing Arthroplasty Surgery. 2019 University of Florida Precision Medicine Conference. Orlando, FL.	March 2019
A Tale of Two Pains: CYP2D6-guided Pain Management. PGRN 2019 Research in Progress Seminar. Webinar.	February 2019
<i>CYP2C19</i> -Proton Pump Inhibitors. Clinical Pharmacogenetics Implementation Consortium Monthly Business Meeting. Webinar.	February 2018

TEACHING AND PRECEPTING EXPERIENCES

Instructor for Patient Care 3: Introduction to Cardiovascular & Pulmonary Disease University of Florida Course number/ID: PHA 5878C	Fall 2024
Guest lecturer for Seminars in Pharmacy Research University of Florida Course number/ID: PHA5930	December 2023
Active Learning Facilitator and Instructor for Clinical Applications of Personalized Medicine – Cardiovascular Pharmacogenetics University of Florida Course number/ID: PHA5012	May 2022 May 2021
Active Learning Facilitator and Instructor for Pharmacogenomics Module University of Florida Course number/ID: PHA5166L	March 2022 March 2021
Guest Lecturer for Clinical Applications of Personalized Medicine – Consumer Based (Direct to Consumer) Genetic Testing University of Florida Course number/ID: PHA5012	April 2021

Guest Lecturer and Active Learning Facilitator for Pharmacogenomic Literature Assessment University of Florida Course number/ID: PHA5040	December 2020
Active Learning Facilitator for Chronic Heart Failure University of Florida Course number/ID: PHA5878C	October 2019
Active Learning Facilitator and Instructor for Pharmacogenomics of Drug Transporters University of Florida Course number/ID: PHA5132	January 2019
Instructor for Pharmacogenomics University of Tennessee Health Science Center Course number/ID: PHSC222	March 2018
University of Florida Teaching Certificate College of Pharmacy	June 2017
Co-preceptor for Student Pharmacists St. Jude Children's Research Hospital UF Health Jacksonville	September 2017 – May 2018 July 2016 – June 2017
Facilitator and Instructor for Professional Skills Lab University of Florida Course number/ID: PHA5162L, PHA5164L	January 2017
Facilitator and Evaluator for Pharmacotherapy V University of Florida Course number/ID: PHA5787	January 2017
Principles of Drug Therapy Individualization University of Florida Course number/ID: PHA5132	January 2017
Critical Care University of Florida Course number/ID: PHA5607	October 2016
Pharmacotherapy IV University of Florida Course number/ID: PHA5784	September 2016

AWARDS & CERTIFICATES

American Society for Clinical Pharmacology & Therapeutics Presidential Trainee Award	2025
--	------

DeSantis Graduate Student Research in Precision Medicine	2024
Fundamentals of Deep Learning – Certificate authorized by NVIDIA Deep Learning Institute	2023
Outstanding Graduate Student Research Award – Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida	2022
Unsupervised Learning, Recommenders, Reinforcement Learning – Course Certificate authorized by DeepLearning.AI and Stanford University	2022
Advanced Learning Algorithms – Course Certificate authorized by DeepLearning.AI and Stanford University	2022
Supervised Machine Learning: Regression and Classification – Course Certificate authorized by DeepLearning.AI and Stanford University	2022
Graduate Student Superhero Award – College of Pharmacy, University of Florida	2022
American Society for Clinical Pharmacology & Therapeutics Presidential Trainee Award	2022
Annual Research Showcase Finalist – College of Pharmacy, University of Florida	2022
American Society for Clinical Pharmacology & Therapeutics Presidential Trainee Award	2021
Annual Research Showcase Finalist – College of Pharmacy, University of Florida	2021
American College of Clinical Pharmacy Research Fellow Trainee Award	2020
American Society for Clinical Pharmacology & Therapeutics Presidential Trainee Award	2020
Pharmacogenomics Global Research Network Trainee Award	2019

PHARMACIST LICENSURE

State of Tennessee – (41416)	2017 – Present
State of Florida – (PS 54994)	2016 – Present